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nloaded fromThe tumor microenvironment is profoundly immunosuppressive. We show that multiple tumor types create intra-
tumoral immune suppression driven by a specialized form of regulatory T cell (Treg) activation dependent on the
PTEN (phosphatase and tensin homolog) lipid phosphatase. PTEN acted to stabilize Tregs in tumors, preventing them
from reprogramming into inflammatory effector cells. In mice with a Treg-specific deletion of PTEN, tumors grew
slowly, were inflamed, and could not create an immunosuppressive tumor microenvironment. In normal mice, ex-
posure to apoptotic tumor cells rapidly elicited PTEN-expressing Tregs, and PTEN-deficient mice were unable to
maintain tolerance to apoptotic cells. In wild-type mice with large established tumors, pharmacologic inhibition
of PTEN after chemotherapy or immunotherapy profoundly reconfigured the tumor microenvironment, changing
it from a suppressive to an inflammatory milieu, and tumors underwent rapid regression. Thus, the immuno-
suppressive milieu in tumors must be actively maintained, and tumors become susceptible to immune attack if
the PTEN pathway in Tregs is disrupted.http
  o
n
 January 6, 201
://advances.sciencem
ag.org/INTRODUCTION
Tumors are not invisible to the immune system (1–4). Analysis of pa-
tients’ T cells suggests that many patients are chronically attempting to
mount an immune response against their own tumors (5–8). However,
in almost all cases, this attempted response is suppressed by potent in-
hibitory mechanisms within the tumor microenvironment. Multiple
mechanisms contribute to this suppression (9), but one key component
is the Foxp3+ regulatory T cell (Treg) system. Tumors actively recruit
Tregs, and the Tregs in tumors become highly activated (10). If Tregs are
transiently ablated in tumor-bearing mice, then the immune system
rapidly attempts to attack the tumor (11, 12). However, in these mod-
els, complete depletion of Tregs leads to lethal autoimmunity, yet partial
depletion of Tregs is not sufficient to reverse the suppressive milieu in
the tumor (13). To date, it has not been possible to preferentially target
the Tregs that are protecting the tumor.
To improve this selectivity, we asked whether tumors might pref-
erentially depend on certain molecular pathways to activate Tregs. This
activation step is a critical control point in Treg biology, because even
fully mature Tregs require specific activation signals to become func- 6tionally suppressive (14). These signals include engagement of the T cell
antigen receptor (TCR) (15, 16). However, antigen specificity alone
does not confer selectivity for tumors, because many of the Tregs in
tumors appear to recognize normal self-antigens (17). Besides anti-
gen, Tregs also integrate a variety of modulating signals from the local
microenvironment during activation (18). This can produce “tailored”
forms of activation, with distinct patterns of transcription factors
and functional activity (19). We hypothesized that the unique envi-
ronment of tumors might preferentially elicit certain characteristic
pathways of Treg activation.
The lipid phosphatase PTEN (phosphatase and tensin homolog)
has recently been identified as an important signaling pathway in Tregs
(20, 21). Targeted deletion of PTEN causes Treg instability (20), leading to
progressive conversion into proinflammatory effector cells (so-called ex-
Tregs), and eventual lupus-like autoimmunity. However, the mechanism
by which PTEN stabilizes Tregs and the role that this might play in tumor
biology remain unknown. Here, we show that many Tregs in the tumor
microenvironment constitutively express PTEN and rely on this pathway
to maintain their suppressive function. PTEN signaling in Tregs is required
for the immune system to suppress responses to apoptotic cells, including
apoptotic tumor cells. If this PTEN pathway is interrupted, then tumors
lose the ability to create their usual highly suppressive milieu. The Tregs in
tumors are destabilized and reprogram into inflammatory effector cells,
the tumor milieu becomes proinflammatory and immunogenic, and
even large established tumors undergo rapid regression.RESULTS
Connection between IDO, PD-1, and PTEN in Tregs
Melanoma tumors in mice contained a large population of activated
Tregs expressing the cell surface receptor programmed cell death-1 (PD-1)
(Fig. 1A and fig. S1). PD-1 is a marker for activated Tregs in tumors (10),
although its functional role remains unknown. The same PD-1+ Tregs
also coexpressed high levels of the Foxp3 binding partner Eos (Ikzf4),1 of 15
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 Fig. 1. PTEN is required to maintain IDO-induced Treg activation. (A) Analysis of peripheral Tregs from LNs of normal mice without tumor or from
TDLNs and tumor of mice with B16F10 tumors, gated on CD4+Foxp3+ T . (B) Proposed model for regulation of Akt by IDO and the PD-1→PTEN pathwayregs
during Treg activation, based on data from figs. S2 to S8. (C and D) Tregs from PTEN
Treg-KO mice or wild-type (WT) controls were activated in vitro for 2 days
with IDO+ DCs from TDLNs, using the coculture system described in fig. S2A. (C) Tregs were analyzed for phosphorylation of Akt by FACS at the end of
activation. (D) After activation, Tregs were re-sorted and tested in readout assays for their ability to maintain FoxO3a and PD-1. (E) PTEN
Treg-KO Tregs or WT
(parental) control Tregs were activated either with IDO
+ DCs from TDLNs or using conventional anti-CD3 mitogen with IDO blocked. After 2 days, Tregs were
re-sorted and tested in readout assays for functional suppressor activity, as in fig. S2A. Each point is the mean of triplicate cocultures; error bars show SD
(most are less than ±5%, smaller than the symbols). *P < 0.01 by analysis of variance (ANOVA) versus PD-1/L blockade (all other groups not significant
versus PD-1/L blockade). (F and G) WT Tregs were activated with either IDO
+ TDLN DCs or conventional aCD3 mitogen and then sorted and tested for
functional suppressor activity (F) in the presence of PTEN inhibitor VO-OHpic. Mean of triplicate cocultures; SD bars are smaller than the symbols; *P < 0.01
by ANOVA versus no VO-OHpic. (G) In parallel experiments, the re-sorted Tregs were recovered at the end of the suppression assay and assessed for their
level of Akt phosphorylation and detectable FoxO3a expression by FACS. Panels are representative of three to five independent experiments each.Sharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015 2 of 15
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 which can be up-regulated in tumors by the immunoregulatory en-
zyme indoleamine 2,3-dioxygenase (IDO), as we have shown (22).
IDO promotes tolerance and immunosuppression in the immune sys-
tem (23), and it can directly activate Tregs in tumors (22, 24). These
same PD-1+ EosHI Tregs also coexpressed PTEN phosphatase (Fig. 1A,
right-hand panels).
To help elucidate the connection between IDO, PD-1, and PTEN
in activated Tregs, we used the in vitro culture system shown in fig. S2.
Resting Tregs were activated by coculture with IDO-expressing dendri-
tic cells (DCs) and activated effector cells. After initial activation by
IDO, the Tregs then became strictly dependent on PD-1 to maintain
their functional activity (fig. S2A). We hypothesized that the IDO and
PD-1 pathways might converge at the level of Akt kinase. In most T cells,
high Akt signaling is required for normal activation; however, Tregs are
unusual in that they must keep Akt signaling low during activation or
else they will lose their suppressive phenotype (25). PD-1 is known to
inhibit Akt via the activation of PTEN phosphatase (26, 27), but the
effect of IDO on Akt was unknown. We found that IDO inhibited
phosphorylation of Akt on Ser473 (fig. S2B). Ser473 is the target of the
mTOR TORC2 complex; consistent with this, pharmacologic inhibition
of mTOR could fully substitute for IDO during Treg activation (fig. S2C).
In vivo, administration of an IDO inhibitor drug to tumor-bearing mice
increased pAkt473 phosphorylation in Tregs (fig. S3). Thus, both IDO
and PD-1 appeared to restrain excessive Akt signaling in activated Tregs.
The phosphorylation status of Akt is only a proxy marker and is
very labile. We sought a more stable biomarker that might reflect the
longer-term impact of dysregulated Akt signaling on the overall Treg
phenotype. The transcription factor FoxO3a is important in Treg
function (28), and it is sensitive to the activity of Akt (29–31). In the
short term, phosphorylation by Akt drives nuclear exclusion of FoxO3a
and blocks its function (32), but in the long term, overactivity of Akt
leads to degradation of FoxO3a (33). Fluorescence-activated cell sorting
(FACS) analysis of Tregs showed that FoxO3a expression was highly
bimodal, with some Tregs expressing none and some having strongly
positive expression (fig. S4). In vitro, after activation cocultures, the
fraction of Tregs that became FoxO3a-positive tracked with the sup-
pressor activity controlled by IDO and mTOR (fig. S5A), whereas on
a cell-by-cell basis, those Tregs that expressed PD-1 also coexpressed
FoxO3a (Fig. 5B). Functionally, Tregs from FoxO3-deficient mice (28)
were selectively unable to mediate the form of suppressor activity cre-
ated by the IDO and PD-1, even though conventional CD3-induced
Treg activity remained intact (fig. S5C). Thus, although FoxO3a itself
was not unique or restricted only to IDO and PD-1 (29, 30), we hy-
pothesized that loss (down-regulation) of FoxO3a could be an inform-
ative biomarker for loss of the suppressive Treg phenotype of interest.
IDO and PD-1 acted sequentially. IDO up-regulated expression of
PD-1 on the Tregs via a process requiring tryptophan depletion and sig-
naling via the amino acid–sensitive GCN2 kinase (34) (figs. S6 and S7,
A to C). PD-1 was then required to maintain the IDO-induced acti-
vation state (fig. S8). If the PD-1 pathway was blocked, then Akt phos-
phorylation rapidly became high, FoxO3a was lost, and suppression
activity was abrogated. On the basis of these findings, we hypothesized
the model shown in Fig. 1B, in which IDO and PD-1 sequentially act
to maintain the suppressive Treg phenotype. The key implication of this
model was that maintenance of the suppressive phenotype required
continuous, ongoing control of Akt: If this control was disrupted, then
the suppressive phenotype was rapidly lost. Thus, the critical leverage
point for continued suppression became PD-1 signaling via PTEN.Sharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015Maintenance of the Treg activation state by PTEN
PTEN is an important target for multiple upstream pathways, because
it inhibits phosphatidylinositol 3-kinase (PI3K) and thus limits phos-
phorylation of Akt (26, 27). In addition to PD-1, PTEN is also down-
stream of neuropilin-1, a potent activator of Tregs (29). To assess the
role of PTEN, we crossed mice bearing a floxed PTEN allele (35) with
Bac-transgenic mice expressing a Cre-GFP (green fluorescent protein)
fusion protein under the Foxp3 promoter (36). This Cre strain deletes
in ~95% of Foxp3+ Tregs (36). Consistent with this, our PTEN
Treg-KO
mice expressed Cre-GFP in ~95% of Foxp3+ cells and showed no de-
tectable PTEN expression in Foxp3+ Tregs from tumors or tumor-
draining lymph nodes (TDLNs) (fig. S9). The phenotype of this particular
Cre/lox intercross was somewhat less penetrant than other PTEN-
deficient strains that have been described (20), in that our mice were
healthy when young and did not develop spontaneous autoimmunity
until later in life (which is an important advantage for tumor studies).
However, even in our young, healthy PTENTreg-KO mice, the Tregs
were unable to control phosphorylation of Akt at Thr308 during Treg
activation in vitro (Fig. 1C) and could not maintain the activated
FoxO3a+ PD-1+ suppressive phenotype after re-sorting (Fig. 1, D
and E). This was not due to a global defect in all Treg activity, be-
cause conventional CD3-induced Treg activity remained intact in these
mice (Fig. 1E). Thus, the defect in PTENTreg-KO Tregs was a selective
one, but—at least in the case of IDO—it profoundly compromised their
ability to maintain the activated Treg phenotype.
We next asked whether PTEN could be pharmacologically targeted.
PTEN inhibitor drugs are under active preclinical investigation for their
neuroprotective and cardioprotective effects; we tested VO-OHpic,
a high-affinity small-molecule inhibitor of PTEN (37), for its ability to
block suppression by IDO-activated Tregs in vitro (Fig. 1F). In the ab-
sence of any Tregs, VO-OHpic had no effect on the readout T cells
(neither toxic nor stimulatory). When control CD3-activated Tregs were
added, VO-OHpic had no effect on their ability to suppress. However,
when the same Tregs were activated by IDO, VO-OHpic fully blocked
their suppressor activity, in a dose-dependent fashion. This was ac-
companied by progressive increase in phosphorylation of Akt in the
Tregs and progressive loss of detectable FoxO3a (Fig. 1G). (In these
studies, Thr308 was the direct target of PTEN→PI3K, and there was
no IDO in the system to inhibit phosphorylation of Ser473; hence, both
increased together as the Tregs became activated.)
Failure to create a suppressive tumor microenvironment in the
absence of PTEN-Tregs
We next tested the effect of PTENTreg-KO hosts on tumor growth.
Aggressive melanoma tumors implanted in PTENTreg-KO hosts grew
much slower than the same tumors implanted in wild-type parental
strains (Fig. 2A). Slower growth was also seen with E.G7 (EL4-OVA)
and LLC tumors (fig. S10). Analysis of immune cells infiltrating the
tumors (Fig. 2B) showed that wild-type hosts contained many PTEN+
Tregs that also coexpressed FoxO3a and PD-1, consistent with a sup-
pressive phenotype. In contrast, the Tregs in PTEN
Treg-KO tumors did
not express FoxO3a or PD-1; instead, they appeared unstable, with many
expressing proinflammatory markers such as interleukin-2 (IL-2),
CD40L, and IL-17 (Fig. 2B, lower panels, and fig. S11). All of these “re-
programmed” Tregs continued to express residual Foxp3 (Fig. 2B, bottom
graph), thus showing that they were derived from former Tregs. The pres-
ence of these unstable, reprogrammed Tregs is consistent with our previous
descriptions of Treg reprogramming in tumors when IDO is blocked3 of 15
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 Fig. 2. Tumors in PTENTreg-KO hosts lose the ability to create a suppressive intratumoral milieu. (A) Growth of B16F10 tumors in PTENTreg-KO hosts
and WT B6 hosts. Pooled data from four experiments, n = 6 to 8 tumors per time point. *P < 0.05 versus WT, and all points thereafter. (B to D) Analysis of
tumor-infiltrating immune cells in B16F10 tumors after 10 days of tumor growth in either PTENTreg-KO or parental Foxp3-GFP-Cre hosts: (B) Tregs, (C) CD8
+ T
cells, and (D) CD11c+ DCs. Representative of a total of nine experiments on days 10, 15, and 22. Intracellular cytokines were measured after 4 hours of
activation with phorbol 12-myristate 13-acetate (PMA)/ionomycin. (E) Tumors were implanted on one side of PTENTreg-KO hosts; then, on day 14, the
phenotype of T cells and DCs within the tumor was compared with pooled contralateral LNs, distant from the tumor. (F) Carboxyfluorescein diacetate
succinimidyl ester (CFSE)–labeled pmel-1 cells, recognizing tumor-associated gp100, were transferred into WT or PTENTreg-KO hosts after a single dose of
cyclophosphamide (CTX) to release tumor antigens. (G) PTENTreg-KO hosts or WT controls were implanted with B16F10 tumors or B16-OVA tumors bearing
a nominal antigen. Mice then received a mixture of two CFSE-labeled responder cells: pmel-1 recognizing gp100 and OT-I recognizing OVA. Mice were
then vaccinated against only the gp100 antigen, and tumors were analyzed 4 days later for evidence of epitope spreading (OT-I activation). (E) to (G) are
representative of at least three experiments each.Sharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015 4 of 15
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 (22, 38). Similar unstable ex-Tregs have been described during au-
toimmunity in mice with targeted deletion of PTEN in Tregs (20).
The tumor-infiltrating CD8+ T cells in PTENTreg-KO hosts ap-
peared more activated (Fig. 2C). Fewer CD8+ cells were PD-1+ (im-
plying an “exhausted” phenotype) and more had an activated phenotype
expressing CD103+, CD69+, and interferon-g (IFN-g). DCs in tumors
from PTENTreg-KO mice also showed a more activated phenotype
(Fig. 2D). More DCs expressed an activated myeloid DC phenotype
of Ly6c+CD11b+CD103+, which has been associated with antitumor
immune surveillance (39). Many of these CD103+ DCs produced IL-6
(bottom panels). This was significant because, as we will show, IL-6
proved to be a key driver of Treg reprogramming. Similar changes were
seen when E.G7 lymphoma tumors were grown in PTENTreg-KO hosts
(fig. S12).
These inflammatory changes were physically localized only to the
tumor and TDLNs (Fig. 2E). Elsewhere in these (young, healthy)
PTENTreg-KO hosts, the T cells and DCs appeared normal. This was
informative, because it showed that the tumor became a potent local
stimulus for inflammation when the host lacked the PTEN-Treg pathway.
In PTENTreg-KO hosts, antigen-specific CD8+ T cells became
aware of tumor-associated antigens after chemotherapy. Mice with
established B16F10 tumors were treated with a single dose of CTX to release
tumor antigens and then received a CFSE-labeled cohort of resting
pmel-1 T cells, reactive with a tumor-associated gp100 antigen. In
PTENTreg-KO hosts, the resting pmel-1 cells became activated and
proliferated in tumors, whereas proliferation was suppressed in
wild-type hosts (Fig. 2F). Similarly, when tumor-bearing mice were
treated with T cell adoptive transfer and antitumor vaccination,
PTENTreg-KO hosts supported generalization of the immune re-
sponse to new, additional T cells, recognizing antigen derived only
from the tumor (Fig. 2G). No such epitope spreading occurred in
wild-type hosts. (In all of these studies, the readout T cells were
purified by negative selection, because this was important to prevent
artifactual activation, as shown in fig. S13.) Thus, taken together, in
PTENTreg-KO hosts, tumors were unable to create their usual sup-
pressive tumor microenvironment and instead were regarded by
the immune system as spontaneously inflammatory and immunogenic.
Reconfiguration of the suppressive microenvironment in
established tumors
We next asked whether a similar antitumor inflammatory response
could be induced in wild-type mice by pharmacologic inhibition of
PTEN. This was a more demanding setting because the tumor had
already established a suppressive milieu. Administering PTEN inhib-
itor by itself had no effect on growth of established tumors; however, if
mice also received immunotherapy (vaccine plus pmel-1 T cells), then
blocking PTEN had a potent effect, allowing rapid regression of tu-
mors (Fig. 3A). Similar results were seen with ovalbumin (OVA)–
expressing EL4 tumors and anti-OVA vaccine (Fig. 3B).
Analysis of treated tumors revealed that phosphorylation of Akt in
Tregs remained low when tumors received only vaccine/T cells alone,
but Akt phosphorylation became high when the PTEN inhibitor was
added (Fig. 3C, red histograms). Phosphorylation was increased at
both Thr308 and Ser473 sites. This is the expected pattern during activa-
tion of conventional (non-Treg) CD4
+ cells (40), but it should not occur
in Tregs, which need to keep Akt activity low. Thus, blocking PTEN
caused dysregulated control of Akt in Tregs. (Notably, the Tregs were
analyzed after 4 days of treatment; thus, Akt phosphorylation reflectedSharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015the whole process of activation and destabilization, over and above the
direct effects of the PTEN inhibitor on Thr308.)
Consistent with their inability to control Akt activity, intratumoral
Tregs in PTEN
Treg-KO mice lost detectable FoxO3a and PD-1 (Fig.
3C, dot plots). They also became destabilized and up-regulated pro-
inflammatory IL-2 and CD40L (that is, underwent reprogramming).
As a biologic control for these effects, we included the PI3K-d inhibitor
CAL-101 (41), which inhibits Treg activity but does not affect PTEN.
When tested in our in vitro model, CAL-101 inhibited Treg activation as
expected, but it was not selective, inhibiting both IDO-induced and CD3-
induced suppression (fig. S14). In vivo, CAL-101 did not increase Akt
phosphorylation in Tregs, did not cause loss of FoxO3a and PD-1, and
did not drive Treg destabilization and reprogramming (Fig. 3C). In our pre-
vious studies of Treg reprogramming, we had shown that TCR-mediated
activation is strictly required for reprogramming to occur (22, 38, 42).
Thus, CAL-101 appeared to inhibit all Treg activation (41), including
the “destabilizing” activation that was required to drive reprogramming,
whereas VO-OHpic allowed activation, but in a destabilizing fashion.
Further characterization of the tumor milieu after VO-OHpic
treatment showed that vaccine-specific OT-I cells were suppressed
when PTEN was active but were able to proliferate and up-regulate
granzyme B when PTEN was blocked (Fig. 3D). Tumors also con-
tained more activated, proinflammatory Ly6c+CD11b+ myeloid DCs
when PTEN was blocked, and the DCs expressed more CD86 and less
PD-L1 (Fig. 3D, lower panels). The contribution of the immuno-
therapy regimen (T cells and vaccine) was important, because success-
ful transformation of the tumor microenvironment required both
vaccine-activated T cells and inhibition of PTEN (Fig. 3E).
Finally, we noted that the PTEN inhibitor itself had no effect on a
normal vaccine response in the absence of tumor (fig. S15A). The
same was true for genetic ablation of PTEN (fig. S15B): In the absence
of a suppressive tumor, ablating PTEN had no effect on the response
to vaccine. Thus, the effect of PTEN inhibition was to reverse the spe-
cific tumor-induced suppression, rather than to nonspecifically aug-
ment all immune responses.
PTEN-Tregs and tolerance to apoptotic cells
PTEN+ Tregs were crucial for tumors, but it was not clear what role
these cells normally played in the immune system. Other strains of
mice with Treg-specific deletion of PTEN develop a spontaneous lupus-
like autoimmunity as they age (20). Such “lupus-prone” phenotypes
can reflect an inability to maintain tolerance to apoptotic cells (43).
We have previously shown that apoptotic cells are potent inducers
of IDO, and IDO-deficient mice fail to create tolerance to apoptotic
cells and instead develop lupus autoimmunity (23). We triggered ap-
optosis in EL4 tumor cells by in vitro treatment with staurosporine for
4 hours, and then injected the apoptotic tumor cells into normal,
tumor-free mice. Apoptotic tumor cells drove extensive up-regulation
of IDO in draining LNs (DLNs) (Fig. 4A). This IDO expression was
functionally important, because mice treated with an IDO inhibitor
became responsive to antigen from the apoptotic cells, whereas re-
sponses were suppressed if IDO was active (Fig. 4B). Apoptotic tumor
cells elicited a prominent population of PTEN+ Tregs expressing FoxO3a
+
and PD-1+ in local DLNs, and induction of these Tregs was blocked by
the IDO inhibitor (Fig. 4C). When Tregs were sorted from DLNs after
challenge with apoptotic cells, these Tregs mediated potent, spontaneous
suppression ex vivo, in the PD-1–dependent fashion characteristic of
IDO-induced activation (Fig. 4D). In contrast, Tregs from resting LNs5 of 15
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 showed no spontaneous suppressor activity. [Readout assays in these
experiments were driven by cognate antigen, with no CD3 mitogen,
and under these conditions, resting Tregs do not show spontaneous
suppression (14).] Thus, apoptotic tumor cells appeared to directly
elicit the IDO-induced, PD-1–dependent PTEN+ FoxO3a+ PD-1+
form of Treg activation.
To test whether these Tregs were mechanistically controlled by
PTEN, we treated mice with the PTEN inhibitor during exposureSharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015to apoptotic cells, and we compared wild-type hosts to PTENTreg-
KO hosts (Fig. 4E). When wild-type mice received VO-OHpic at the
time of challenge, apoptotic cells elicited no FoxO3a+PD-1+ Tregs (Fig.
4E, top row). Instead, the apoptotic cells now induced inflammatory
CD11b+CD103+ myeloid DCs, and the readout OT-I T cells were able
to respond to antigens from apoptotic cells (lower rows). Similar results
were seen when genetically defined PTENTreg-KO mice were challenged
with apoptotic cells (Fig. 4E, right-hand plots). In these PTENTreg-KOmice,Fig. 3. Vaccination drives rapid reconfiguration of the suppressive tumor microenvironment when PTEN is blocked. (A and B) WT C57Bl/6 mice
with established B16F10 tumors (A) or E.G7 tumors (B) were treated with tumor-specific T cells (pmel-1 or OT-I) plus cognate vaccine, with or without
VO-OHpic [10 mg kg−1 day−1 intraperitoneally (ip)] as indicated. Each curve represents pooled data from a total of 6 to 22 tumors in three to five
independent experiments, measured serially. *P < 0.01 versus all other curves by ANOVA. (C) B16F10 tumors received vaccine and pmel-1 cells as in
(A), with or without either VO-OHpic or CAL-101 (PI3K-d inhibitor, 30 mg kg−1 day−1 ip). Tumors were harvested 4 days after vaccine and stained for Akt
phosphorylation in gated GFP+ Tregs and for evidence of Treg destabilization and reprogramming. Representative of five experiments. (D) Effect of VO-OHpic
on intratumoral OT-I responses and activation of tumor-associated DCs in mice with E.G7 tumors, treated with OT-I/vaccine as in (B), with or without
VO-OHpic. Similar results were seen using B16F10 with pmel-1/hgp100 vaccine. (E) Requirement for both VO-OHpic and activated OT-I/vaccine to suc-
cessfully drive Treg destabilization and DC activation in established E.G7 tumors. (D) and (E) are representative of at least three experiments each.6 of 15
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 Fig. 4. The PTEN pathway in Tregs is required to suppress immune responses to apoptotic cells. (A to D) Normal mice without tumors received
footpad injection of dying EL4 tumor cells (treated for 3 hours in vitro with staurosporine to induce apoptosis). (A) After 48 hours, DLNs and unaffected
contralateral LNs (CLNs) were stained for IDO (red chromogen). (B) OT-I response to cell-associated antigen from apoptotic EL4-OVA (E.G7) cells, or pa-
rental EL4 controls, with or without treatment in vivo with the IDO inhibitor drug in drinking water. (C) After apoptotic cell injection, Foxp3+ Tregs were
compared in DLNs versus control distant CLNs for activation of PTEN-Tregs, with or without IDO inhibitor (indoximod). (D) Two days after challenge with
apoptotic cells, Tregs were sorted from DLNs (or control LNs without injection) and directly tested ex vivo for constitutive suppressor activity, as described
in fig. S2A, with or without PD-1/L blockade in the readout assay. Each point is the mean of triplicate cocultures; bars show SD (all are less than ±5%,
smaller than the symbols). (E) Effect of PTEN inhibitor (VO-OHpic) on the immune response to apoptotic EL4-OVA cells (E.G7). Responses were compared
in WT (parental) hosts and PTENTreg-KO hosts, with and without VO-OHpic. (F) Old mice (1- to 2-year-old retired breeders) and young mice (<6 months)
from the PTENTreg-KO strain were tested for spontaneous antinuclear autoantibodies in serum (ANA, left) and deposition of immunoglobulin G (IgG) and
complement C3 in the kidney (right). (G and H) Young, healthy PTENTreg-KO mice, or control WT B6 mice, were challenged with 2 × 107 apoptotic
thymocytes weekly for four doses intravenously. Splenic B cells were analyzed for CD24 expression on day 28 (G). Serum titers of autoantibodies were
compared at days 0, 14, and 28 (H). Pooled data from four to five mice; bars show SD.Sharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015 7 of 15
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 there was no additional effect of adding VO-OHpic, suggesting that the
PTEN expressed in Tregs was an important target of VO-OHpic in this
model.
On the basis of the response to apoptotic tumor cells, we asked
whether the PTENTreg-KO mice had a generalized defect in tolerance
to all apoptotic cells. Although the mice in our strain were healthy
when young, some of the older mice (>1 year) spontaneously devel-
oped antinuclear antibody and immune complex deposition in the
kidney, consistent with lupus-like autoimmunity (Fig. 4F). Therefore,
to test the younger, asymptomatic PTENTreg-KO mice for an under-
lying defect in tolerance, we challenged them with intravenous injec-
tion of apoptotic thymocytes. These were syngeneic cells, and wild-type
mice were fully tolerant to them; however, the PTENTreg-KO mice
showed widespread B cell activation (assessed as loss of CD24,
Fig. 4G) and rapidly developed multiple autoantibodies against classic
apoptotic cell antigens (nucleosome, double-stranded DNA, and his-
tone; Fig. 4H). Thus, when confronted with large numbers of apoptotic
cells, the PTEN pathway in Tregs appeared critical for the host to create
immune suppression and tolerance.
Synergy between chemotherapy and PTEN inhibition
Chemotherapy releases a wave of dying tumor cells. We hypothesized
that the tumor might become critically dependent on the PTEN
pathway after chemotherapy. Mice bearing established B16F10 tumors
received a single injection of CTX, with or without VO-OHpic (Fig.
5A). The dose of CTX was modest and by itself had no effect on these
resistant tumors. VO-OHpic alone also had no effect on tumor
growth. However, together these agents displayed striking synergy,
causing rapid shrinkage of the tumor within 4 to 5 days. Mice received
no other immunotherapy or T cell transfer; hence, any immunologic
effects were the spontaneous contribution of the host immune system.
Chemotherapy plus VO-OHpic was well tolerated, without weight loss
or other obvious toxicity. In validation studies, mice without tumors
were treated with VO-OHpic for up to 21 days and did not develop
detectable autoantibodies (fig. S16).
In this chemotherapy model, inhibiting PTEN caused much more
potent synergy than inhibiting IDO, which causes growth delay but
not tumor regression as we have previously shown (44). However,
combining an IDO inhibitor with VO-OHpic conferred additional
benefit, delaying the regrowth of the tumor and prolonging the dura-
tion of response (fig. S17A). This was consistent with our in vitro mod-
el, in which PTEN maintained the function of Tregs that were already
activated, but IDO contributed to activation of new Tregs. LLC lung
carcinoma tumors also showed synergy between chemotherapy and
inhibition of PTEN (fig. S17B).
Immune activation after chemotherapy when PTEN
is inhibited
When PTEN was inhibited, the response of the host immune system
to chemotherapy became fundamentally changed. Phosphorylation of
Akt in Tregs went up (Fig. 5B), with associated loss of FoxO3a expres-
sion (Fig. 5C). Tregs were destabilized, as shown by reprogramming
(expression of IL-2 and CD40L, Fig. 5C, lower panels). DCs acquired
the activated myeloid DC phenotype (CD11b+CD103+) and many
began to express IL-6, whereas PD-L1 was reduced and CD86 was
markedly increased (Fig. 5D). In contrast, the Tregs and DCs from
control mice receiving the PI3K-d inhibitor CAL-101 showed none
of these changes (Fig. 5, B to D). Functionally, both CAL-101 andSharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015VO-OHpic enhanced the antitumor effect of CTX, but VO-OHpic
drove more sustained tumor regression (fig. S18). We hypothesized
that the response to VO-OHpic might be related to the beneficial in-
flammatory effects of the destabilized (reprogrammed) Tregs. To test
this, tumors were grown in mice with a transgenic diphtheria toxin re-
ceptor (DTR) under the control of the Foxp3 promoter, thus allowing
global depletion of Tregs by administration of diphtheria toxin (DT, fig.
S19). Ablation of Tregs with DTmodestly enhanced the effect of CTX, but
this effect was much less than the effect of VO-OHpic, and tumors
showed no regression. When mice received both VO-OHpic and Treg
ablation, the superior efficacy of VO-OHpic was lost, and the response
became equivalent to DT ablation alone. Thus, the destabilized Tregs
appeared to be an important driver of the antitumor response.
To directly test this, we bred mice that lacked the ability to undergo
Treg reprogramming by ablating the IL-6 receptor on Tregs (IL6R
Treg-KO
mice). We have previously shown that IL-6 is required to drive Treg
reprogramming (22, 38), which has also been seen by others (45, 46).
Tregs from IL6R
Treg-KO mice were unable to reprogram in vitro (fig.
S20A). In vivo, treatment with CTX + VO-OHpic lost all antitumor
effect (fig. S20, B and C). Thus, Treg reprogramming was functionally
required for the synergy between VO-OHpic and chemotherapy,
consistent with the role of PTEN in maintaining Treg stability (20, 21).
We next tested the contribution of effector CD8+ T cells. Studies in
Rag-deficient mice showed that adaptive immunity was strictly re-
quired (Fig. 5E). To follow a known population of tumor-reactive
CD8+ T cells during treatment, we pretransferred a cohort of Thy1.1
congenic pmel-1 T cells into normal wild-type host mice before im-
planting tumors (Fig. 5F). In untreated mice, pmel-1 cells in the tumor
appeared unactivated (no expression of CD69, 1B11, or IFN-g) and
many expressed PD-1, suggestive of an exhausted phenotype. In con-
trast, when mice were treated with CTX + VO-OHpic, the pmel-1 cells
in tumors down-regulated PD-1, and many now expressed CD69,
1B11, and IFN-g. Finally, we used antibody-mediated depletion to deter-
mine whether endogenous CD8+ T cells were required. Depletion of
CD8+ cells completely abrogated the antitumor effect of CTX +VO-OHpic
(Fig. 5G), and the intratumoral Tregs did not lose their FoxO3a
+ PD-1+
(suppressive) phenotype. This was consistent with our previous reports
(22) showing that Treg destabilization is an active process, driven by
activated effector T cells.
Together, across multiple experiments using B16F10, EL4, LLC, and
autochthonous Tg(Grm1)Epv tumors, we observed consistent recon-
figuration of the tumor milieu into a proinflammatory phenotype after
CTX + VO-OHpic (Fig. 5H). These changes closely recapitulated the
spontaneous changes seen when tumors were grown in genetically de-
fined PTENTreg-KOmice (cf. Fig. 2). Similarly, fig. S21 shows that tumors
in wild-type mice treated with CTX + VO-OHpic became indistinguish-
able from tumors grown in PTENTreg-KO hosts, whereas, conversely,
tumors grown in PTENTreg-KO mice showed no further discernible
effect of CTX + VO-OHpic. Thus, although PTEN can be expressed
in multiple cell types, its expression in Tregs appeared to be an important
target of VO-OHpic in tumor-bearing hosts.
Rapid regression of autochthonous tumors
Autochthonous tumors coevolve with the host immune system. This
creates profound immune tolerance, and such tumors are much more
resistant to the immunologic effects of chemotherapy than transplantable
tumors (47). To test the role of PTEN in a demanding autochthonous
setting, we used Tg(Grm1)Epv mice (48), which express the oncogenic8 of 15
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 Fig. 5. Blocking PTEN allows rapid, spontaneous reconfiguration of the suppressive tumor milieu after chemotherapy. (A) WT B6 mice with
established B16F10 tumors were treated with a single dose of CTX (150 mg kg−1 ip) with or without VO-OHpic (10 mg kg−1 day−1 ip). Tumor volume
is shown. Pooled data from five independent experiments; n = 10 to 16 tumors in each group; bars show SD. *P < 0.01 versus all other groups by ANOVA.
(B to D) Mice with B16F10 tumors were treated as in (A) with CTX plus either VO-OHpic, CAL-101, or vehicle. (B) Phosphorylation of Akt in tumor-associated
Tregs was assessed 4 days after CTX [numbers show the mean fluorescence intensity (MFI) of the positive population]. (C) Treg reprogramming in tumors
after chemotherapy. Inset histograms show reduction in Foxp3 fluorescence with VO-OHpic. (D) DC activation in tumors after chemotherapy with VO-OHpic.
(E) Rag1-KO hosts or WT B6 controls treated with CTX plus VO-OHpic. Mean of 16 tumors from two independent experiments; bars show SD (the bars in
the WT group are smaller than the symbols). *P < 0.01 by ANOVA. (F) B6 mice received 2 × 106 Thy1.1-congenic resting pmel-1 cells and then were implanted
with B16F10 tumors. After 9 days, mice received either CTX + VO-OHpic or no treatment, and the phenotype of pmel-1 cells in tumors was analyzed on day
14. Representative of three experiments. (G) The effect of CTX + VO-OHpic is abrogated by antibody-mediated depletion of CD8+ cells. FACS analysis of
tumor-infiltrating cells from representative tumors is shown on the right. n = 6 tumors per group, pooled from three independent experiments, *P < 0.01 by
ANOVA. (H) Aggregate phenotyping data for immune cells infiltrating tumors treated with CTX, with or without VO-OHpic. The number of independent
experiments for each marker is given, with P value by two-tailed paired t test. Lines connect the two groups in each experiment.Sharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015 9 of 15
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nloaGrm1 receptor under the melanocyte-specific Trp2 promoter. These
mice progressively develop extensive multifocal melanomas on the ears
and tail. When tumors became extensive (4 to 6 months of age), mice
were treated with one dose of CTX plus VO-OHpic for 6 days. After
treatment, even large, multifocal confluent tumors rapidly regressed
(Fig. 6A). As a measure of regression, we used ear thickness as a proxy,
because all ears were extensively involved with tumor (inset graph, Fig.
6A). Control groups receiving chemotherapy alone, VO-OHpic alone, or
no treatment all showed no detectable effect (shown as the pooled
controls on the graph). All the effects of CTX + VO-OHpic were lost
when mice received depleting monoclonal antibody (mAb) against CD8
(upper inset graph), confirming that the effect was immune-dependent.
Histologically, regression was accompanied by a selective elimination of
the melanotic tumor cells, leaving underlying tissue intact (Fig. 6B).
FACS analysis of regressing tumors showed emergence of the char-
acteristic Ly6c+CD11b+-activated myeloid DCs (Fig. 6C), identical to
those in the transplantable tumor models mentioned earlier. Tumor-Sharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015infiltrating host CD8+ T cells lost their PD-1+ exhausted phenotype
and up-regulated granzyme B (Fig. 6D). All Tregs in the tumor lost
detectable FoxO3a and PD-1 expression after treatment (Fig. 6E),
and the Tregs became unstable and began to express CD40L and IL-2
(Fig. 6F). Thus, even in mice with extensive, multifocal autochthonous
tumors, a single dose of chemotherapy caused rapid and widespread
tumor regression when PTEN was inhibited.DISCUSSION
Here, we identify PTEN signaling in Tregs as an important, centrally
positioned driver of the immunosuppressive milieu in tumors. When
this pathway was active, Tregs in tumors were highly suppressive; the
antigen-presenting cell (APC) population was dominated by PD-L1–
expressing DCs, with little evidence of inflammation or cross-presentation,
and CD8+ T cells appeared unactivated and exhausted in the tumor. o
n




 Fig. 6. Extensive autochthonous melanoma tumors regress after chemotherapy plus PTEN inhibitor. Tg(Grm1)Epv mice with extensive, multifocal
autochthonous melanomas were treated with a single dose of CTX plus VO-OHpic as shown. Some mice also received concurrent CD8-depleting antibody
as described in Materials and Methods. (A) Regression of tumors on the ears and tail (ears are from representative mice; tails are before and after). Inset
graph: quantitation of ear thickness (proxy for tumor involvement) after treatment. n = 10 to 16 ears per group serially measured from three independent
experiments; bars show SD. *P < 0.01 by ANOVA versus all other groups. The “pooled controls” group contains CTX alone and VO-OHpic alone, neither of
which showed any effect. To estimate tumor regression, we subtracted the normal thickness of healthy mouse ear (0.6 ± 0.03 mm, n = 12) and then we
expressed the serial tumor measurements as percent change relative to the original pretreatment baseline for that ear. (B) Histology on day +4 of CTX/
VO-OHpic [hematoxylin and eosin (H&E) stain; tumor cells are visible as black melanotic lesions]. Representative of four experiments. (C to F) Phenotype of
cells from disaggregated tumor (several pooled tumors from the same mouse). Representative of five independent experiments.10 of 15
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 In contrast, if the PTEN pathway was ablated in Tregs, then the same
tumors became spontaneously inflammatory and immunogenic: Tregs
in the tumor (but not elsewhere) lost their suppressive phenotype and
converted into proinflammatory helper cells (ex-Tregs); the major DC
population was changed into a characteristic population of activated
myeloid DCs expressing Ly6c, CD11b, and CD103 and producing IL-6;
costimulation (CD86) went up and co-inhibition (PD-L1) went down;
and CD8+ T cells became activated in the tumor. Thus, the PTEN
pathway in Tregs dominantly regulated a suite of critical downstream
pathways.
Tumors rely on multiple immunosuppressive mechanisms; thus,
PTEN-Tregs are a part of a larger network, but it was striking that a
single pathway in a single cell type was so crucial for the overall im-
munologic milieu of the tumor. PTEN-Tregs were found in three different
transplantable tumors and in each of the spontaneous tumors tested in
an autochthonous tumor model. It is not yet known how these differ-
ent tumors all converged on the same suppressive pathway, but insight
may come from our finding that PTENTreg-KO mice were unable to
suppress immune responses to apoptotic cells. Tumors are aberrant
and have a high rate of constitutive cell turnover—in many respects,
they resemble chronic wounds (49). This chronic, ongoing cell death
can become massively increased after chemotherapy or immuno-
therapy. Thus, the ability to enforce immune suppression in response
to apoptotic cells may be an important immune-evasion pathway for
tumors, particularly under the stress of chemotherapy or vaccination.
PTEN had connections to the IDO pathway. IDO-activated Tregs
became dependent on PD-1→PTEN signaling to maintain their sup-
pression, whereas apoptotic tumor cells actively induced PTEN-Tregs in
an IDO-dependent fashion. However, the tumor-resistant phenotype
of PTENTreg-KO mice was much more robust than that of IDO1-KO
mice, and blocking PTEN had a more acute antitumor effect than
blocking IDO alone. PTEN is downstream of other important Treg-
activating signals as well, such as neuropilin-1 (29). Thus, PTEN ap-
pears to be an important nexus for multiple upstream signals in Treg
biology. This makes it an attractive target for therapy.
Pharmacologic inhibition of PTEN was synergistic with chemo-
therapy. In the case of the melanoma models [B16F10 and Tg(Grm1)
Epv], this synergy was dramatic. Different tumor types displayed differ-
ent degrees of regression after CTX + VO-OHpic, and some tumors
may recruit more myeloid-derived suppressor cells or other mecha-
nisms that are not as dependent on PTEN. Part of the susceptibility
of various tumors may be dictated by the strength of the spontaneous,
preexisting CD8+ T cell response against the tumor. Using depletion
studies, we found that endogenous host CD8+ T cells were strictly re-
quired for the antitumor effect of chemotherapy + PTEN inhibitor. In
addition to being cytotoxic effector cells, these CD8+ cells appeared to
play an important role as drivers of inflammation. Without the endog-
enous CD8+ cells, intratumoral Tregs never lost their suppressive pheno-
type, and there was no downstream activation of inflammatory myeloid
DCs. Thus, although blocking PTEN rendered the Tregs unstable in the
face of inflammation, the CD8+ T cells were required to actually trigger
that inflammation itself and thus drive reprogramming.
This role for inflammation and T cells differs from the older con-
cept that the immune system might contribute some of the intrinsic
efficacy of standard chemotherapy (that is, chemotherapy used by it-
self) (50). Our model does not speak to this, because we deliberately
chose a chemotherapy regimen that had no efficacy by itself against
the tumor. It was only when the PTEN inhibitor was added, andSharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015new immunologic mechanisms were now unleashed, that the com-
bined chemoimmunotherapy regimen showed efficacy. It was this
new, synergistic effect of the combination that was strictly immune-
dependent.
PTEN-Tregs were indispensable for regulating the immune response
to apoptotic cells. In mice without tumors, simply injecting apoptotic
tumor cells caused rapid local activation of PTEN-Tregs, and T cell re-
sponses to cell-associated antigens were suppressed. However, if PTEN
was blocked or ablated, then the same apoptotic tumor cells were now
treated as proinflammatory and caused activation of DCs and cross-
presentation of antigen to T cells. Thus, whether the host treated ap-
optotic cells as immunogenic or tolerogenic was not intrinsic to the
dying cells themselves, but rather was a choice enforced by the acti-
vated PTEN-Tregs. Consistent with this, when PTEN
Treg-KO mice were
challenged with repetitive injections of apoptotic thymocytes, they ra-
pidly developed multiple lupus-like autoantibodies. This phenotype is
very similar to IDO1-deficient mice, challenged with the same regimen
of apoptotic cells (23), which is consistent with our finding that apo-
ptotic cells induced PTEN-Tregs via IDO. Thus, we hypothesize that one
normal role of the PTEN-Treg pathway is to maintain self-tolerance to
apoptotic cells, and this natural tolerogenic pathway is pathologically
co-opted by tumors.
Other strains of mice lacking PTEN in Tregs spontaneously develop
lupus autoantibodies as they age (20, 21). Our mice, using a different
Cre system and different PTEN-floxed mice, had a somewhat milder
phenotype and did not develop autoantibodies until late in life. How-
ever, both strains developed the same lupus-like autoimmunity, with its
characteristic autoantibody response against antigens derived from ap-
optotic cells. The fact that our strain had late onset of disease was cru-
cial, because it allowed us to demonstrate the markedly and
fundamentally altered underlying response to tumors, even in healthy,
asymptomatic young mice.
The role of PTEN in self-tolerance introduces the possibility of au-
toimmune side effects when PTEN inhibitors are used therapeutically.
Autoimmunity is always a potential “on-target” toxicity for strategies
that aim to break tolerance to tumor cells (51). However, the PTEN
pathway has several attributes that make it attractive for clinical ther-
apy. First, the required duration of inhibitor treatment is brief, being
focused just on the specific period when tumor cells are undergoing
cell death after chemotherapy or vaccination. Second, the tumor
appears to be heavily dependent on the PTEN-Treg pathway for immu-
nosuppression, much more so than normal tissues. This was shown by
the spontaneous inflammation seen within the tumor in young,
healthy PTENTreg-KO mice but not seen anywhere else outside the
tumor. Third, tumors are mutated and hence potentially more immu-
nogenic than normal tissues (52). This may contribute to the “driver”
CD8 response needed to initiate inflammation within the tumor.
Together, these factors may allow brief, focused dosing with the
PTEN inhibitor to achieve selective effects on the tumor while mini-
mizing autoimmune toxicity. The use of intermittent dosing also mit-
igates the hypothetical concern that PTEN inhibitors might be
oncogenic. PTEN is a tumor-suppressor gene, but it is not a trans-
forming oncogene; thus, to have an oncogenic effect, it must be
inhibited for a prolonged period and also combined with additional
driver oncogenes. Hence, transient intermittent interruption and res-
toration of PTEN should not be an oncogenic regimen and may ac-
tually cause senescence in tumor cells (53). Together, our findings
identify the PTEN pathway in Tregs as an important driver of the11 of 15
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 MATERIALS AND METHODS
Reagents
Indoximod (1-methyl-D-tryptophan) and NLG919 were supplied as
clinical-grade material by NewLink Genetics Inc. For in vitro studies,
indoximod was dissolved in alkaline pH as previously described (34)
and diluted in phosphate-buffered saline (PBS) at a final pH of 7.4.
Rapamycin (Sigma #R8781) was used at 85 nM. PP242 (Seleckchem
#S2218) was used at 100 nM. Human gp10025–33 (KVPRNQDWL) and
SIINFEKL peptides were synthesized by Southern Biotechnology from
the published sequence (54, 55). VO-OHpic (BioVision #1801-5) was
used at 1 mM in vitro unless otherwise specified (37) and at 10 mg kg−1
day−1 in vivo, administered in 10% dimethyl sulfoxide (DMSO). CAL-101
(Seleckchem #S2226) was used at 200 nM in vitro and at 30 mg kg−1
day−1 in vivo, administered in 10% DMSO.
Treg/DC cocultures
Initial activation cocultures. Our Treg coculture system has been
previously described (22, 24). Cocultures were performed in V-bottom
wells (Nunc 249952 V96) to ensure cell-cell contact. Rapid isolation of
Tregs was important; hence, LNs and spleen were mechanically disag-
gregated by passing once through a 40-mm mesh and then briefly
stained on ice and FACS-sorted into ice-cold medium using low-shear
fluidics and a large nozzle. IDO+ DCs (5 × 103 per well) were enriched
from TDLNs of B16F10 tumors (days 7 to 11) by sorting for CD11c+
cells, which typically contained 30 to 40% IDO+ DCs (24); because the
effects of IDO were dominant, further fractionation was not necessary.
Resting Tregs (2 × 10
4 per well) were sorted as CD4+GFP+ cells from
spleens of Foxp3GFP, Foxp3DTR-GFP, or Foxp3GFP-Cre mice; all three strains
gave equivalent results. CD8+ effector cells (5 × 104) were FACS-sorted
from spleens of OT-I or pmel-1 mice and added to cocultures with
100 nM cognate peptide (either SIINFEKL or hgp100). All cultures re-
ceived a feeder layer of 1 × 105 T cell–depleted B6 spleen cells
(CD4NEGCD8NEG) to maintain Treg viability, as previously described
(24). Cultures received either indoximod (200 mM) or NLG919 (1 mM)
to inhibit IDO. For aCD3-induced activation, cocultures received
aCD3 mAb (0.1 mg/ml; clone 145-2C11, azide-free); in addition, these
cultures also always received an IDO inhibitor to ensure that IDO was
not active or inducible during coculture.
Treg re-sorting and readout assays. After 2 to 3 days (the time was
not critical), activation cocultures were harvested, cells were stained for
CD4, and the activated Tregs were re-sorted as CD4
+GFP+ cells. For
readout assays, sorted Tregs were added to V-bottom wells containing
5 × 104 FACS-sorted CD8+ effector cells (OT-I or pmel-1, as used in
the original activation cultures) plus 5 × 103 CD11c+ DCs sorted from
normal LNs of mice without tumors. Some wells received blocking anti-
bodies against the PD-1 pathway, as a cocktail (each 50 mg/ml) of anti–
PD-L2, clone TY25 (56); anti–PD-1, clone J43 (57); and anti–PD-L1,
clone MIH7 (58) (a gift of M. Azuma). After 3 days, cocultures were
analyzed by flow cytometry or were pulsed with [3H]thymidine to mea-
sure proliferation.
Ex vivo Treg assays from vaccine-draining LNs. To measure spon-
taneous Treg activity in vaccine-draining LNs (VDLNs), we implanted
B16F10 tumors in Foxp3-GFP reporter mice. On day 11, mice receivedSharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015hgp100 vaccine in CpG/IFA (incomplete Freund’s adjuvant) in the con-
tralateral footpad, with intravenous pmel-1 adoptive transfer. Three days
later, the VDLNs were harvested and CD4+GFP+ Tregs were sorted and
added to readout assays as described in the preceding section.
Antibodies and FACS staining
LNs were prepared by rapidly passing through a 40-mm mesh and
then stained using short incubation times (10 min on ice), as previously
described (22). Tumors were disaggregated by treating for 1 hour with
collagenase (1 mg/ml; C5138, Sigma), deoxyribonuclease (0.1 mg/ml;
D5025, Sigma), and hyaluronidase (0.1 mg/ml; H3884, Sigma) in
RPMI 1640 medium.
Conjugated mAbs against the following were from BD Biosciences:
CD4 (clone RM4-5), CD8a (clone 53-6.7), CD80 (clone 16.10A1),
CD86 (clone GL1), CD11c (clone HL3), Ly6c (clone AL-21), PTEN
(A2B1), CD25 (clone PC61), IFN-g (clone XMG1.2), CD24 (clone
M1/69), and B220 (clone RA3-6B2). Conjugated antibodies against
the following were obtained from eBioscience: Foxp3 (clone FJK-16s),
granzyme B (clone NGZB), PD1 (clone J43), PD-L1 (cloneMIH5), PD-L2
(clone 122), CD103 (Ber-ACT8) and Ly6c (clone HK1.4), CD278 (ICOS,
clone 7E.17G9), CD69 (clone H1.2F3), IL-2 (clone JES6-5H4), IL-17A
(clone 17B7), CD40L (clone MR1), IL-6 (clone MP5-20F3), CD11b
(clone M1/70), and CD126 (clone D7715A7). Clone 1B11 (glycosylated
CD43) was from BioLegend.
Intracellular antigens were detected using a fixation-permeabilization
reagent and a matching perm-wash buffer from eBioscience (catalog
#00-5521), with blocking using 5% normal donkey serum, and then
acquired immediately after staining. IL-2, IFN-g, and IL-6 were
measured after 4 hours of activation with PMA/ionomycin in the
presence of brefeldin A as previously described (22). Unconjugated
anti-FoxO3a (4 mg/ml; rabbit mAb, clone 75D8, Cell Signaling Tech-
nology) was used in the perm-wash buffer and was detected with don-
key anti-rabbit PE (Jackson ImmunoResearch #711-116-152) at 1:100
dilution. All washes were performed in the perm-wash buffer in the
cold. Goat anti-Eos (sc-132308) (2 mg/ml) from Santa Cruz Biotech-
nology was used, followed by cross-adsorbed secondary donkey anti-
goat APC (705-136-147) from Jackson ImmunoResearch as previously
described (22).
For phospho-specific staining, antibodies were from Cell Signaling
Technology, either Alexa Fluor 647–conjugated pAkt-Thr308 (catalog
#3375), pAkt-Ser473 (catalog #4075), or anti-pS6 (catalog #4851). Cells
were washed in PBS, fixed with 2% paraformaldehyde for 10 min at
37°C, prechilled for 1 min, and then permeabilized by slow addition of
ice-cold methanol to a final concentration of 90%. Cells were then in-
cubated on ice for 30 min, washed with 1% fetal calf serum/PBS,
blocked with the same solution for 10 min at room temperature and
then for 1 hour at room temperature, and washed. Cells were acquired
immediately after staining.
Mouse strains
All animal studies were approved by the Institutional Animal Care
and Use Committee of Georgia Health Sciences University. FoxO3-
deficient mice (FoxO3Kca strain) have been previously described
(28) and were the gift of S. Hedrick and the Ludwig Institute for Cancer
Research. The following were obtained from the Jackson Laboratory
and bred in our colony: OT-I mice [CD8+, recognizing the SIINFEKL
peptide of OVA on H2Kb (55)] and pmel-1 mice [B6.Cg-Thy1a/
CyTg(TcraTcrb)8Rest/J, recognizing a peptide from human gp100 (54)].12 of 15
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 IDO-deficient mice (B6 background) have been previously described
(59, 60). PD-1–deficient mice have been previously described (26).
Tregs were identified using GFP reporter mice. To ensure that results
were not influenced by a particular reporter strain, we confirmed them
using multiple reporter systems. Foxp3GFP mice (61, 62), bearing a
Foxp3-GFP fusion protein in the coding region of the Foxp3 locus, were
the gift of A. Rudensky. Foxp3DTR mice, with a DTR-GFP fusion
construct knocked in to the 3′ untranslated region of the Foxp3 gene
(but with a normal Foxp3 coding sequence), were the gift of A. Rudensky
(63). Mice with a BAC-transgenic GFP-Cre fusion protein under the
Foxp3 promoter (Foxp3GFP-Cre) (36, 64) were obtained from the Jackson
Laboratory [NOD/ShiLt-Tg(Foxp3-EGFP/cre)1Jbs/J] and backcrossed
in our colony onto the B6 background. These were used for intercrosses
with floxed alleles to create Treg-specific deletions, as follows.
PTENTreg-KO mice: Foxp3GFP-Cre mice, as described above, were
crossed with mice bearing loxP sites flanking exon 5 of the PTEN gene
(B6.129S4-Ptentm1Hwu/J, Jackson Laboratory) (35). The resulting strain
was maintained as hemizygous for GFP-Cre and homozygous for
PtenloxP/loxP.
FoxO3Treg-KO mice: Foxp3GFP-Cre mice were crossed with mice
bearing loxP sites flanking exon 2 of the Foxo3 gene (a gift of R. DePinho
and the Dana-Farber Cancer Institute) (65). The resulting strain was main-
tained as hemizygous for GFP-Cre and homozygous for Foxo3loxp/loxp.
These mice were used as controls to validate the specificity of FoxO3a
intracellular staining.
IL6RaTreg-KO mice: Foxp3GFP-Cre mice were crossed with mice bear-
ing loxP sites flanking exons 4 to 6 of the IL-6 receptor a-chain (Il6ra)
gene (B6;SJL-Il6ratm1.1Drew/J, Jackson Laboratory) (66). The resulting
strain was maintained as hemizygous for GFP-Cre and homozygous
for IL6raloxp/loxp.
Tumor studies
The Tg(Grm1)Epv mouse strain (48) was the gift of S. Chen (Rutgers
University). The B16F10, EL4, E.G7, and LLC cell lines were from the
American Type Culture Collection. B16-OVA (B16F10 transfected
with full-length chicken OVA) clone MO4 (67) was the gift of A.
Houghton (Memorial Sloan Kettering). Tumor implantation was per-
formed as previously described (24), using 1 × 105 cells for B16F10
and 1 × 106 cells for other cell lines (large inocula were used to ensure
rapid tumor engraftment and immune suppression). Tumor volume
was calculated from orthogonal diameters using the formula V = L ×
W2 × p/6. Indoximod (2 mg/ml) was administered in drinking water
as previously described (24), and NLG919 (6 mg/ml) was similarly
administered. VO-OHpic was given at 10 mg kg−1 day−1 ip in 10%
DMSO. CAL-101 was given at 30 mg kg−1 day−1 ip in 10% DMSO.
For in vivo CD8 depletion studies, mice received anti-CD8 antibody
clone YTS 169.4 (BioXcell) given at 200 mg ip 1 day before CTX and
then at 100 mg ip every other day throughout the experiment. Indox-
imod (2 mg/ml; D-1MT) was administered in drinking water as pre-
viously described (24). Mice received approved euthanasia when
tumors reached a size of 300 mm2 (product of orthogonal diameters);
death was not used as a planned end point in any study.
Vaccines and T cell adoptive transfers
CpG-1826 (phosphorothioate oligo 5′-TCCATGACGTTCCTGAGCTT-
3′) was synthesized from the published sequence (68) by TriLink Bio-
technologies. Whole OVA protein was from Sigma (#A-5503). Human
gp10025–33 was synthesized from the published sequence (54). VaccinesSharma et al. Sci. Adv. 2015;1:e1500845 6 November 2015were prepared with 100 mg of OVA protein or 25 mg of peptide, with
50 mg of CpG-1826 in IFA (Sigma F-5506) and administered in the
hindlimb footpad. Popliteal LNs were harvested 4 days later. For all
adoptive transfers, OT-I or pmel-1 spleen cells were enriched by neg-
ative selection using magnetic beads (mouse CD8 isolation kit II,
#130-095-236, Miltenyi Biotec). Staining for bead isolation was performed
on ice, with short incubation times. Mice received 2 × 106 enriched CD8+
cells via the tail vein.
Statistics
Multiple treatment groups were compared by ANOVA with Tukey’s
honestly significant difference correction. Independent replicates for
each experiment in the manuscript are indicated in the figure legends.
Error bars always show SD.SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/1/10/e1500845/DC1
Methods
Fig. S1. Extended phenotyping of Treg population in LNs of normal mice, in TDLNs of mice with
B16F10 tumors, and in the disaggregated tumors themselves.
Fig. S2. Role of IDO, PD-1, and mTOR pathways during Treg activation in vitro.
Fig. S3. In vivo phosphorylation status of S6 and Akt473 in Tregs from TDLNs of tumor-bearing
mice, after vaccination in the presence or absence of IDO inhibitor drug (2 mg/ml in drinking
water, or vehicle control, as indicated).
Fig. S4. Confirmation of specificity of the FoxO3a staining antibody (rabbit monoclonal, clone
75D8, Cell Signaling Technology).
Fig. S5. Foxo3a in activated Tregs in vitro.
Fig. S6. Activation step cocultures using IDO+ TDLN DCs were supplemented with excess
tryptophan at the concentrations shown.
Fig. S7. IDO was important in controlling Akt phosphorylation, but it was unclear how
IDO, which was expressed in the DCs, influenced the mTOR→Akt473 pathway expressed
in Tregs.
Fig. S8. Role of PD-1 in maintaining IDO-induced suppressor activity.
Fig. S9. Validation of PTENTreg-KO mice.
Fig. S10. Growth of EL4-OVA (E.G7) and LLC tumors in PTENTreg-KO hosts.
Fig. S11. Spontaneous reprogramming of Tregs in tumors of PTEN
Treg-KO mice.
Fig. S12. Inflammatory intratumoral milieu in E.G7 tumors grown in PTENTreg-KO hosts.
Fig. S13. Artifactual preactivation by CD8 bead isolation obscures immunosuppression by
tumors.
Fig. S14. Tregs were activated using IDO
+ TDLN DCs (left) or with aCD3 mitogen and IDO
blocked (right).
Fig. S15. Effect of PTEN blockade or genetic deletion on response to vaccination.
Fig. S16. Absence of autoantibodies in mice receiving VO-OHpic.
Fig. S17. Combination of VO-OHpic with indoximod.
Fig. S18. Comparison of VO-OHpic versus CAL-101 when given in combination with CTX.
Fig. S19. B16F10 tumors were grown in mice bearing an insertion of a fusion protein of GFP
with the human DTR into the Foxp3 locus (63).
Fig. S20. Requirement for IL-6 receptor expression on Tregs for Treg destabilization and anti-tumor
response.
Fig. S21. PTENTreg-KO mice lose any further effect of the VO-OHpic PTEN inhibitor.REFERENCES AND NOTES
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